Anne  Kasus-Jacobi , Ph.D.

Assistant Professor of Research

Department of Pharmaceutical Sciences

Phone (405) 271-1484 (Lab)  x(405) 637-3432 (Cell)
Fax (405) 271-7505
Office   CPB 255

Research Summary

My research interests are focused on the role of the antimicrobial protein CAP37 in vision-threatening conditions and diseases. Specifically, our goal is to develop CAP37-derived therapeutic peptides that promote corneal wound healing, prevent and treat difficult bacterial infections of the cornea, and prevent inflammation-driven diseases of the posterior segment of the eye such as age-related macular degeneration or diabetic retinopathy.

Education & Experience

  • Postdoctoral Fellow, University of Texas, Dallas. Molecular Genetics. 2004
  • Ph.D., Endocrinology. University of Paris XI, France. 1998.
  • M.S., Cell Biology. University of Paris VII. France. 1993.
  • B.S., Cell Biology. University of Paris VII. France. 1992.


  • Assistant Professor of Research, Dept. of Pharmaceutical Sciences, OU College of Pharmacy. OKC, OK. 2011-present.
  • Assistant Professor of Research, Dept. of Ophthalmology, OU Health Sciences Center. OKC, OK. 2004-2011.
  • Postdoctoral Researcher, Dept. of Molecular Genetics. Univ. of Texas Southwestern Medical Center. Dallas, TX. 1998-2004.
  • Graduate Student, Laboratoire d'Endrocrinologie Metabolisme et Developpement, CNRS UPR 1524, Meudon, France. 1994-1998.
  • Research Assistant, Laboratoire de Pharmacologie et des Transports Ioniques, Univ. of Paris VII. France. 1991-1992.

Honors & Service

Awards: Travel awards to present results in international meetings, from the Association for Research in Vision and Ophthalmology Foundation (2006), the National Eye Institute (2004), the International Society for Eye Research (2004), and the Keystone Symposia (1998).


  • US Provisional patent appliation, 16 Apr 2014; HA Pereira, A Kasus-Jacobi, GL Briffith; "Wound healing and antibacterial compounds and methods of use."
  • US Provisional patent application, 03 Dec 2014; HA Pereira, A Kasus-Jacobi, GL Griffith; "CAP37 peptids as therapeutics in wound healing."
  • US Patent application, 03 Dec 2013; HA Pereira, A Kasus-Jacobi, GL Griffith; "Peptide compounds and methods of production and use thereof.:
  • US Patent US6867003 B1, 15 Mar 2005; A-F Burnol, D Perdereau, A Kasus-Jacobi, V Bereziat, J Girard; "Grb14, Grb14 fusion proteins, and screening methods."
  • Current Grants Awarded

  • Identification of membrane receptor(s) for CAP37 and CAP37-derived chemotactic peptides. The objective of this proposal is to generate preliminary results using the TriCEPS method for ligand-based receptor capture, using the CAP37 chemotactic ligands and the human corneal epithelial cells, to validate the utilization of this technical approach. OU College of Pharmacy Seed Grant, Anne Kasus-Jacobi (PI), 01/01/2015-12/31/2015.
  • Role of CAP37 in Neuroinflammation: Friend or Foe? The major goal of this project is to determine the role of CAP37 in neuroinflammation. Oklahoma Center for the Advancement of Scient and Technology (OCAST), HR-12-068, H. Anne Pereira (PI), Anne Kasus-Jacobi (Collaborator), 07/01/12-06/30/15.
  • Completed:
  • Therapeutic use of carcinine n progressive retinopathy. The major goal of this project was to determine whether carcinine can be used to prevent photoreceptor damage in Leber Congenital Amaurosis and Retinitis Pigmentosa mouse models. Oklahoma Center for the Advancement of Science and Technology (OCAST), HR-10-152, Anne Kasus-Jacobi (PI), 10/01/10-09/30/13.
  • Detoxification role of retinol dehyrogenases RDH11 and RDH12. The major goals of this project were (1) To characterize the catalytic activities of RDH11 and RDH12 towards 4-HNE in vitro and in mouse retina; and (2) To determine whether RDH11 and RDH12 are protective against the formation of 4-HNE-protein adducts and the apoptosis of photoreceptors ex vivo and in vivo. NIH/NEI, R21EY018907, Anne Kasus-Jacobi (PI), 10/01/08-09/30/10.